The potential of melanoma antigen expression in cancer therapy

Cancer Treatment Reviews

Volumn 25, Issue 4, 1999, Pages 219-227

  Gillespie, Alan M ^a   Coleman, Robert E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Cancer immunotherapy; MAGE; Tumour associated antigen

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CD45 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELANOMA ANTIGEN;

CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; HUMAN; IMMUNOHISTOCHEMISTRY; MULTIGENE FAMILY; PROTEIN EXPRESSION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

EID: 0032861160     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0126     Document Type: Review

References (79)

1. Coley W. B. The treatment of malignant tumours by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. 105:1893;487.
2. Gross L. Intradermal immunisation of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 31:1943;326-333.
3. Foley E. J. Antigenic properties of methylcholanthrene-induced tumours in mice of the strain of origin. Cancer Res. 13:1953;835-837.
4. Prehn RT and Main J. M. Immunity to methylcholanthrene-induced sarcomas. J Nat Cancer Inst. 18:1957;769-778.
5. Hewitt H. B., Blake ER and Walder A. S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 33:1976;241-259.
6. Lewis JL and Houghton A. N. Definition of tumour antigens suitable for vaccine construction. Semin Cancer Biol. 6:1995;321-327.
7. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A and Boon T. A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643-1647.
8. Boon T. Teaching the immune system to fight cancer. Sci-Am. 268:1993;82-89.
9. De Plaen E., Arden K., Traversari C., Gaforio J. J., Szikora J-P., De Smet C., Brasseur F., van der Bruggen P., Lethe B., Lurquin C., Brasseur R., Chomez P., De Backer O., Cavenee W and Boon T. Structure chromosomal localization and expression of 12 genes of the MAGE family. Immunogenetics. 40:1994;360-369.
10. Oaks M. X., Hanson J. P. Jr, O' Malley D. P. Molecular cytogenetic mapping of the human melanoma antigen (MAGE) gene family to chromosome region Xq27-qter: implications for MAGE immunotherapy. Cancer Res. 54:1994;1627-1629.
11. Muscatelli F., Walker A. P., De Plaen E., Stafford AN and Monaco A. P. Isolation and characterization of a MAGE gene family in the Xp2 1.3 region. Proc Natl AcadSci USA. 92:1995;4987-4991.
12. Imai Y., Shichijo S., Yamada A., Katayama T., Y ano H and Itoh K. Sequences analysis of the MAGE gene family encoding human tumor-rejection antigens. Gene. 160:1995;287-290.
13. Ding M., Beck R. J., Keller CJ and Fenton R. G. Cloning and analysis of MAGE1 related genes. Biochem Biophys Res Commun. 202:1994;549-555.
14. Rogner U. C., Wilke K., Steck E., Korn B., Poustka A. The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics. 29:1995;725-731.
15. Amar-Costesec A., Godelaine D., Stockert E., van der Bruggen P., Beaufay H and Chen Y. T. The tumor protein MAGE-1 is located in the cytosol of human melanoma cells. Biochem Biophys Res Commun. 204:1994;710-715.
16. Schultz-Thater E., Juretic A., Dellabona P. Luscher U, Siegrist W, Harder F, Heberer M, Zubre M and Spagnoli GC. MAGE-1 gene product is a cytoplasmic protein. Int J Cancer. 59:1994;435-439.
17. Kocher T., Schultz-Thater E., Gudat F., Schaefer C., Casorati G., Juretic A., Willimann T., Harder F., Heberer M and Spagnoli G. C. Identification and intracellular location of MAGE-3 gene product. Cancer Res. 55:1995;2236-2239.
18. Traversari C., van der Bruggen P., Luescher IF., Lurquin C., Chomez P., Van Pel A., De Plaen E., Amar-Costesec A., Boon T. A nonapeptide encoded by human gene MAGE-1 is recognised on HLA-A 1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 176:1992;1453-1457.
19. van der Bruggen P., Szikora J-P., Boel P., Wildmann C., Somville M., Sensi M., Boon T. Autologous cytolytic T lymphocytes recognise a MAGE-1 nonapeptide on melanomas expressing HLA-Cw(*)1601. Eur J Immunol. 24:1994;2134-2140.
20. Gaugler B., Van Den Eynde B., van der Bruggen P., Romero P., Gaforio JJ., De Plaen E., Lethé B., Brasseur F., Boon T. Human gene MAGE-3 codes for an antigen recognised on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 179:1994;921-930.
21. van der Bruggen P., Bastin J., Gajewski T., Coulie PG., Boel P., De Smet C., Traversari C., Townsend A., Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognise tumor cells expressing MAGE-3. Eur J Immunol. 24:1994;3038-3043.
22. Celis E., Fikes J., Wentworth P., Sidney J., Southwood S., Maewal A., Del Guercio M. F., Sette A., Livingston By. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol Immunol. 31:1994;1423-1430.
23. Luescher I. F., Romero P., Kuznetsov D., Rimoldi D., Coulie P., Cerottini JC., Jongeneel CV. HLA photoaffinity labeling reveals overlapping binding of homologous melanoma associated gene peptides by HLA-A1, HLA-A29, and HLA-B44. J Biol Chem. 271:1996;12463-12471.
24. Takahashi K., Shichijo S., Noguchi M., Hirohata M., And Itoh K. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res. 55:1995;3478-3482.
25. Mulcahy K. A., Rimoldi D., Brasseur F., Rodgers S., Lienard D., Marchand M., Rennie I. G., Murray AK., McIntyre CA., Platts KE., Leyvraz S., Boon T., Rees RC. Infrequent expression of the MAGE gene family in uveal melanomas. Int J Cancer. 66:1996;738-742.
26. Chen P. W., Murray T. G., Salgaller M. L., Ksander B. R. Expression of MAGE genes in ocular melanoma cell lines. J Immunother. 20:1997;265-275.
27. Chen P. W., Murray T. G., Uno T., Salgaller M. L., Reddy R., Ksander B. R. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin Exp Metastasis. 15:1997;509-518.
28. Corrias V., Scaruffi P., Occhino M., De Bemardi B., Tonini G. P., Pistoia V. Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. Int J Cancer. 69:1996;403-407.
29. Ishida H., Matsumura T., Salgalire M. L., Ohmizono Y., Kadono Y., Sawada T. MAGE-1 and MAGE-3 or - 6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer. 69:1996;375-380.
30. Shichijo S., Tsunosue R., Masuoka K., Naton H., Tamai M., Miyajima J., Sagawa K and Itoh K. Expression of the MAGE gene family in human lymphocytic leukemia. Cancer Immunol Immunother. 41:1994;90-103.
31. Carrel S., Schreyer M., Spagnoli G., Cerottini JC and Rimoldi D. Monoclonal antibodies against recombinant MAGE-1 protein identify a cross-reacting 72-kDa antigen which is co-expressed with MAGE- 1 protein in melanoma cells. Int J Cancer. 67:1996;417-422.
32. Yamada A., Kataoka A., Shichijo S., Kamura T., Imai Y., Nishida T and Itoh K. Expression of MAGE- 1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumours. Int J Cancer. 64:1995;388-393.
33. Kuramoto T. Detection of MAGE-1 tumor antigen in brain tumor. Kurume Med J. 44:1997;43-51.
34. Gudat F., Zuber M., Durmuller U., Kocher T., Schaefer C., Noppen C., Spagnoli 0. The tumour associated antigen MAGE-1 is detectable in formalin-fixed paraffin sections of malignant melanoma. Virchows Arch. 429:1996;77-81.
35. Shichijo S., Hoshino T., Koufuki K., Hayashi A., Kawamoto M., Kikuchi M., Higuchi T., Ichiki M., Gizumi K., Itoh K. Detection of MAGE-4 protein in sera of lung cancer patients. Jpn J Cancer Res. 88:1997;414-419.
36. Iwamoto O., Nagao Y., Shichijo S., Eura M., Kameyama T., Itoh K. Detection of MAGE-4 protein in sera of patients with head and neck squamous cell carcinoma. Int J Cancer. 70:1997;287-290.
37. Toh Y., Yamana H., Shichijo S., Fujita H., Tou U., Sakaguchi M., Kakegawa T and Itoh K. Expression of MAGE-1 gene by esophageal carcinomas. Jpn J Cancer Res. 86:1995;714-717.
38. Patard J-J., Brasseur F., Gil-Diez S., Radvanyi F., Marchand M., Francois P., Abi-Aad A., Van Cangh P., Abbou CC., Chopin D., Boon T. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer (PredOncol). 64:1995;60-64.
39. Shichijo S., Hayashi A., Takamori S., Tsunosue R., Hoshino T. R., Sakata M., Kuramoto T., Oizumi K and Itoh K. Detection of MAGE-4 protein in lung cancers. Int J Cancer. 64:1995;158-165.
40. Mori M., Inoue H., Mimori K., Shibuta K., Baba K., Nakashima H., Haraguchi M., Tsuji K., Ueo H., Barnard OF and Akiyoshi T. Expression of MAGE genes in human colorectal carcinoma. Ann Surg. 224:1996;183-188.
41. Eura M., Ogi K., Chikamatsu K., Lee K. D., Nakano K., Masuyama K., Itoh K., Ishikawa T. Expression of the MAGE gene family in human head and neck squamous cell carcinomas. Int J Cancer. 64:1995;304-308.
42. Brasseur F., Rimoldi D., Liénard D., Lethé B., Carrel S., Arienti F., Suter L., Vanwijck R., Bourlond A., Humblet Y., Vacca A., Conese M., Lahaye T., Degiovanni G., Deraemaecker R., Beauduin M., Sastre X., Salamon E., Dréno B., Jager E., Knuth A., Chevreau C., Suciu S., Lachapelle J-M., Pouillart P., Parmiani G., Lejeune F., Cerottini J-C., Boon T., Marchand M. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer. 63:1995;375-380.
43. Katano M., Nakamura M., Morisaki T., Fujimoto K. Melanoma antigen-encoding gene- 1 expression in invasive gastric carcinoma: correlation with stage of disease. J Surg Oncol. 64:1997;195-201.
44. Russo V., Traversari C., Verrecchia A., Mottolese M., Natali PG and Bordignon C. Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer. 64:1995;216-221.
45. Inoue H., Mori M., Li J., Mimori K., Honda M., Nakashima H., Mafune K., Tanaka Y., Akiyoshi T. Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer. 63:1995;523-526.
46. Gillespie A. M., Rodgers S., Wilson A. P., Tidy J., Rees R. C., Coleman RE and Murray A. K. MAGE, BAGE and GAGE: Tumour antigen expression in benign and malignant ovarian tissue. Br J Cancer. 78:1998;816-821.
47. Becker J. C., Gillitzer R., Brocker E. B. A member of the melanoma antigen-encoding gene (MAGE) family is expressed in human skin during wound healing. Int J Cancer. 58:1994;346-348.
48. 1-deoxycytidine. Cancer Res. 54:1994;1766-1771.
49. 1-deoxycytidine. Jpn J Cancer Res. 87:1996;751-756.
50. De Smet C., De Backer O., Faraoni I., Lurquin C., Brasseur F and Boon T. The activation of human gene MAGE- 1 in tumor cells is correlated with genomewide demethylation. Proc Natl Acad Sci USA. 93:1996;7149-7153.
51. Serrano A., Garcia A., Abril E., Garrido F., Ruiz-Cabello F. Methylated CpG points identified within MAGE-1 promoter are involved in gene repression. Int J Cancer. 68:1996;464-470.
52. Uyttenhove C., Godfraind C., Lethe B., Amar-Costesec A., Renauld J. C., Gajewski T. F., Duffour M. T., Warnier G., Boon T., Van den Eynde B. J. The expression of mouse gene PiA in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int J Cancer. 70:1997;349-356.
53. Celis E., Tsai V., Crimi C., DeMars R., Wentworth P. A., Chesnut R. W., Grey H. M., Sette A and Serra H. M. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Nat Acad Sci USA. 91:1994;2105-2109.
54. Toso J. F., Oei C., Oshidari F., Tartaglia J., Paoletti E., Lyerly J. K., Talib S., Weinhold K. J. MAGE-1 specific precursor cytotoxic T lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen specific activation. Cancer Res. 56:1996;16-20.
55. Valmori D., Lienard D., Waanders G., Rimoldi D., Cerottini J. C., Romero P. Analysis of MAGE-3 specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res. 57:1997;735-741.
56. Yamasaki S., Okino T., Chakraborty N. G., Adkisson W. O., Sampieri A., Padula S. J., Mauri F and Mukherji B. Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage colony stimulating factor cultured macrophages from HLA-A1 melanoma patients. Cancer Immunol Immunother. 40:1995;268-271.
57. Mukherji B., Chakraborty N. G., Yamasaki S., Okino T., Yamase H., Sporn J. R., Kurtzman S. K., Ergin M. T., Ozols J and Meehan J. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA. 92:1995;8078-8082.
58. Hu X., Chakraborty N. G., Spron J. R., Kurtzman S. H., Ergin M. T., Mukherji B. Enhancement of cytolytic T lymphocytes precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 56:1996;2479-2483.
59. Hoon D. S., Yuzuki D., Hayashida M., Morton D. L. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J lmmunol. 154:1995;730-737.
60. Marchand M., Weynants P., Rankin E., Arienti F., Belli F., Parmiani F., Cascinelli N., Bourlond A., Vanwijck R., Humblet Y., Canon J. L., Laurent C., Naeyaert J. M., Plagne R., Deraemaeker R., Knuth A., Jaeger E., Brasseur F., Herman J., Coulie PG and Boon T. Tumor regression responses in melanoma patients treated with a peptide encode by gene MAGE-3. Int J Cancer. 63:1995;883-885.
61. Jaeger E., Bernhard H., Romero P., Ringhoffer M., Arand M., Karbach J., Ilsemann C., Hagedorn M., Kauth A. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumour vaccines with melanoma-associated antigens. Int J Cancer. 66:1996;162-169.
62. Jaeger E., Ringhoffer M., Dienes H. P., Aranol M., Karbach J., Jager D., Ilsemann C., Hagedorn M., Oesch F and Knuth A. Granulocyte-macrophage-colonystimulating factor enhances immune responses to melanoma-associated peptides invivo. Int J Cancer. 67:1996;54-62.
63. Hoon D. S., Wang Y., Dale P. S., Conrad A. J., Schmid P., Garrison D., Kuo C., foshag L. I., Nizze AJ and Morton D. L. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol. 13:1995;2109-2016.
64. van Groeningen C. J., Leyva A., O'Brien A. M., Gall HE and Pinedo H. M. Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 46:1986;4831-4836.
65. 1-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia. 7:1993;36-41.
66. Boel P., Wildmann C., Sensi M. L., Brasseur R., Renauld J. C., Coulie P., Boon T and van der Bruggen P. BAGE: a new gene encoding on antigen recognised on human melanomas by cytolytic T lymphocytes. Immunity. 2:1995;167-175.
67. Van den Eynde B., Peeters O., De-Backer O., Gaugler B., Lucas S and Boon T. A new family of genes coding for an antigen recognised by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med. 182:1995;689-698.
68. Fujie T., Mori M., Ueo H., Sugimachi K and Akiyoshi T. Expression of MAGE and BAGE genes in Japanese breast cancers. Annals of Oncology. 8:1997;369-372.
69. Inoue H., Mori M., Honda M., Li J., Shibuta K., Mimori K., Ueo H and Akiyoshi T. The expression of tumour-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology. 109:1995;1522-1525.
70. Chi D. D., Merchant R. E., Rand R., Conrad A. J., Garrison D., Turner R., Morton DL and Hoon D. S. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol. 150:1997;2143-2152.
71. Lee K. D., Eura M., Ogi K., Nakano K., Chikamatsu K., Masuyama K and Ishikawa T. Expression of the MAGE-1, -2, -3, -4 and -6 genes in non-squamous cell carcinoma lesions of the head and neck. Acta Otolaryngol Stockh. 116:1996;633-639.
72. Yamashita N., Ishibashi H., Hayashida K., Kudo J., Takenaka K., Itoh K and Niho Y. High frequency of the MAGE-1 gene expression in hepatocellular carcinoma. Hepatology. 24:1996;1437-1440.
73. Weynants P., Lethé B., Brasseur F., Marchand M and Boon T. Expression of MAGE genes by non-small-cell lung carcinomas. Int J Cancer. 56:1994;826-829.
74. Sakata M. Expression of MAGE gene family in lung cancers. Kurume Med J. 43:1996;55-61.
75. Eura M., Chikamatsu K., Ogi K., Nakano K., Masuyama K and Ishikawa T. Expression of genes MAGE-1, -2 and -3 by human maxillary carcinoma cells. Anticancer Res. 15:1995;55-59.
76. Quillien V., Raoul J. L., Heresbach D., Collet B., Toujas L and Brasseur F. Expression of MAGE genes in osophageal squamous-cell carcinoma. Anticancer Res. 17:1997;387-391.
77. Sudo T., Kuramoto T., Komiya S., Inoue A and Itoh K. Expression of MAGE genes in osteosarcoma. J Orthop Res. 15:1997;128-132.
78. Lurquin C., De-Smet C., Brasseur F., Muscatelli F., Martelange V., De Plaen E., Brasseur R., Monaco A. P., Boon T. Two members of the human MAGEB gene family located in Xp21-3 are expressed in tumours of various histological origins. Genomics. 46:1997;397-408.
79. Lucas S., De-Smet C., Arden K. C., Viars C. S., Lethe B., Lurquin C and Boon T. Identification of a new MAGE gene with tumour-specific expression by representational difference analysis. Cancer Res. 58:1998;743-752.